Lower Complication Rates in Sludge vs Gallstone Pancreatitis
Patients with sludge- or microlithiasis-induced acute pancreatitis (AP) had significantly lower rates of pancreaticobiliary complications than those with gallstone-induced AP.
METHODOLOGY:
Researchers enrolled 789 patients who were hospitalised with their first episode of biliary pancreatitis between January 2018 and April 2020 at 16 Spanish and two Mexican centres.
Patients were divided into two groups on the basis of types of calculi: those with sludge- or microlithiasis-induced AP (n = 274; median age, 71.9 years; 53.2% women) and gallstone-induced AP (n = 515; median age, 68.9 years; 54.3% women), with neither group receiving cholecystectomy during admission.
The primary endpoint was the rate of pancreaticobiliary complications, measured as the complication-free survival rate, in patients with sludge- or microlithiasis-induced vs those with gallstone-induced AP.
The multivariate analysis was conducted to assess the effect of multiple variables on complication-free survival.
The median follow-up duration was 8.15 months for the sludge/microlithiasis AP cohort and 6.13 months for the gallstone AP cohort (P < .001).
TAKEAWAY:
Patients with gallstone-induced AP had a significantly higher rate of pancreaticobiliary complications than those with sludge- or microlithiasis-induced AP (41.75% vs 32.12%; P = .01).
Patients in the gallstone AP group had a significantly lower complication-free survival rate than those in the sludge/microlithiasis AP group (log-rank P = .0022).
The most frequent complication was recurrent AP, occurring in 24.08% of patients in the gallstone AP group and 20.07% of those in the sludge/microlithiasis AP group.
The medium Charlson Comorbidity Index was independently associated with a higher risk for pancreatobiliary complications for the sludge/microlithiasis AP cohort (hazard ratio [HR], 2.07; P = .005). In the gallstone AP group, older age was associated with a reduced risk for pancreaticobiliary complications (HR, 0.54; P < .001).
IN PRACTICE:
"The lower complication rate observed during follow-up supports, for the first time, the consideration of the sludge/microlithiasis AP cohort as a distinct clinical entity — one that may warrant a more conservative interventional approach, particularly in patients with elevated perioperative risk," the authors of the study wrote.
SOURCE:
This study was led by Simon Sirtl, MD, LMU University Hospital, Munich, Germany. It was published online on June 28, 2025, in Digestive and Liver Disease.
LIMITATIONS:
The study's retrospective design precluded prospective stratification depending on the newly published consensus definitions for biliary sludge and microlithiasis. The inability to stratify patients along with only 17.1% of patients undergoing endoscopic ultrasound introduced heterogeneity into the sludge/microlithiasis AP cohort as the classification remained examiner dependent. Furthermore, the sample size was calculated for pancreatobiliary complications in symptomatic cholelithiasis rather than specifically for AP.
DISCLOSURES:
The trial was funded by AEG Young Talent Grant 2021. One author reported receiving funding from the Deutsche Forschungsgemeinschaft (German Research Foundation) and the LMU Munich Clinician Scientist Program.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 minutes ago
- CBS News
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump super political action committee MAGA Inc. aims to raise about $25 million, one of the sources said. One day prior to the event, Mr. Trump sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug prices to more evenly match what other countries pay. The White House's letters to 17 drug companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi, asked for commitments within 60 days to sell drugs for Medicaid patients and all new drugs at "most favored nation" rates. The president posted images of the letters to Truth Social. Mr. Trump signed an executive order in May telling federal officials to draw up "most favored nation" regulations unless pharmaceutical companies made progress toward cutting prices. This week's letters — which were addressed to Bourla and the other CEOs — accused the drugmakers of promising "more of the same" since then. The president said Friday he's "gone to war with the drug companies and, frankly, other countries" on the drug price issue. "I think we're going to be very successful fairly soon. We'll have drug prices coming down by 500, 600 800 even 1,200 percent," Mr. Trump said in an interview with Newsmax on Friday afternoon. The high cost of prescription drugs has vexed both parties for decades. Proposals to tie drug prices for U.S. patients to the typically much-lower rates charged in other developed countries have floated around for years, but the idea has faced some legal pushback. Meanwhile, drugmakers argue price caps could discourage innovation by making it harder to pay for research and development for new drugs. The industry also argues that Americans tend to have access to more groundbreaking drugs than residents of foreign countries with stricter price regulations — and says high drug prices are just one part of a broader trend of higher healthcare spending in the U.S. Bourla has engaged with Mr. Trump in the past. Pfizer was one of the drugmakers that was picked to rapidly develop COVID-19 vaccines in the first Trump administration's "Operation Warp Speed." And two weeks before Mr. Trump's second inauguration, Bourla and other Pfizer executives traveled to Mar-A-Lago for meetings, the Financial Times has previously reported. CBS News has reached out to Pfizer and the White House for comment.
Yahoo
an hour ago
- Yahoo
How one small clinic proves hepatitis C doesn't have to be an epidemic
Although it's been over a decade since game-changing curative drugs for hepatitis C were approved, progress has been slow and treatment remains out of reach for many. But one small clinic in Buffalo, New York, is proving that doesn't have to be the case. Hepatitis C is a silent epidemic in the U.S., affecting up to 4 million people, according to the Centers for Disease Control and Prevention. Many people don't know they have it. Left untreated, the disease can cause cirrhosis and liver cancer. With a model that's faster, more accessible and remarkably effective, La Bodega, a clinic at Erie County Medical Center, is curing patients at a staggering rate. One of those patients is Lindsey Groffenberg, who quit drugs and was cured of Hep C at La Bodega. "When you're coming out of addiction, and you're trying to recover, the last thing you want is to feel small," she told CBS News. "When I entered La Bodega, I asked them, 'So, when's the doctor gonna come in?' And he said, 'I am the doctor.'" That doctor was Dr. Tony Martinez. "One of our mottos is 'come one, come all,'" Martinez told CBS News. "It's a very safe, stigma-free space, you know, I think people feel that when they come here." Groffenberg now helps others navigate recovery. Success stories like hers have made the clinic a model program. La Bodega gets Hep C patients on treatment in a single visit, and has a track record of curing about 98% of its 7,000-plus patients. New FDA-approved testing machines help speed up treatment. The testing machines, Martinez explained, allow them to see a patient and in that same visit confirm their diagnosis and initiate their meds. As drug costs have dropped, access should have improved, yet so far, less than a third of Americans with Hep C have been treated. Success stories like La Bodega's have policymakers seeking a national plan to eliminate Hep C. In Washington, a bipartisan bill backed by Senators Bill Cassidy and Chris Van Hollen would invest federal funds into wiping out the disease. The average patient with Hep C can rack up as much as $46,000 a year in medical costs. Treating patients early could save the government an estimated $7 billion over a decade. "This is a monumental step forward for anybody who has Hep C — they'd get access to medications," Martinez. Arkansas officials reveal new details about Devil's Den murders of husband and wife Reporter's Notebook: Diane Arbus' photography legacy Exhibition of influential photographer Diane Arbus' work opens in New York
Fox News
an hour ago
- Fox News
Ex-NBA star's wife bitten by shark in Puerto Rico
The pregnant wife of former NBA star Danilo Gallinari revealed on Friday that she had been attacked by a shark in Puerto Rico. Eleonora Boi posted a photo of herself in a hospital bed with her tongue sticking out on her Instagram page with an explanation of the terrifying event. She's expecting her third child with the former New York Knicks forward. She described it as the "worst day of my life." "I never thought I could get attacked by a shark and I was near the shore and on a super crowded beach. Thankfully me and my baby are fine," she wrote, according to a translation. "I was rushed to the rescue and the surgery to fix my poor bruised leg went well. Now I just have to recover from the great scare. . . ." She joked that the shark would be hearing from her lawyer and thanked her husband for his "courage" during the situation. She reportedly suffered a wound on her thigh. Department of Natural and Environmental Resources biologist Nilda Jiménez told El Nuevo Dia that officials were investigating the type of shark that bit Boi. "Based on the photographs provided to us, we believe the characteristics of the bite could be consistent with those of a shark," Nilda told the outlet, via E! News. "But to validate this, a series of analyses would be necessary. For this purpose, medical personnel were asked for samples, which, if available, would be analyzed promptly." Gallinari didn't address the incident. The Italy native played in the NBA from 2008 to 2024 with eight different teams over his career. He averaged 14.9 points and 4.7 rebounds in 777 career games.
